8481-177 Grp B ABA Group B ABA

Back To Current Studies

1 Short Stay

Study Number

8481-177 Grp B ABA


Group B ABA




18 - 55


Madison, Wisconsin



Study Dates

Feb. 15 - 23, 2023

Additional Information

This is a research study for an investigational drug being developed for the treatment of Duchenne muscular dystrophy, Becker muscular dystrophy, certain sub-types of limb-girdle muscular dystrophy, and metabolic myopathies.

This type of study is called a radiolabeled study. The study drug has been specially prepared to contain radiolabeled carbon [14C], a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study drug does not change how the drug works, but helps us to see how the drug appears in the blood, urine, and stool after it is given to you.

The purpose of Part B of this study is to measure how much of the study drug and its breakdown products get into the bloodstream, urine, and/or stool, and how long it takes the body to get rid of them. In addition, the safety and tolerability of the study drug will be evaluated. You will be given a single, oral dose (tablets) of the study drug followed two hours later by a single intravenous (IV) dose over 2 minutes.

Part B requires one in-clinic confinement of up to 9 days/8 nights. 

Labcorp Madison, WI is recruiting for:

- Healthy Males, age 18-55

- Body Mass Index between 18-32

- Study involves 1 stay of 8 nights

- Compensation up to $3,330 may be provided for time and participation

- Receive up to $200 per qualified participant


Check-In: Feb 15, 2023

Check-Out: Feb 23, 2023

Calculate Your BMI!

Your Height:
ft / in
Your Weight:
Select Measurement System:

Your BMI: result